Loading...

Home
ETF
EDIT

EDIT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

EDIT News

Editas Medicine Q4 Earnings Beat Expectations

1d agoseekingalpha

Three Genomics Stocks Worth Adding to Your Portfolio

Nov 18 2025NASDAQ.COM

Janux Therapeutics, Inc. (JANX) Announces Q3 Loss but Exceeds Revenue Projections

Nov 07 2025NASDAQ.COM

Gene Editing Therapy Firms Surge Following News of Simplified FDA Approval Process

Oct 31 2025SeekingAlpha

Intellia Halts Major Trial Following Severe Liver Incident, Shares Plummet

Oct 27 2025Benzinga

After-Hours Surge Boosts PALI, HCTI, NTRB, KPTI, EDIT, and CGON Amid Mixed News and Strategic Actions

Oct 10 2025NASDAQ.COM

Editas Medicine Presents In Vivo Proof-of-Concept Findings for EDIT-401 at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

Oct 09 2025Newsfilter

Healthcare Innovation Speeds Up with Four Key Forces Promoting Early Intervention

Sep 25 2025Newsfilter

My Leading Biotech Stock Selections and Investment Approach for the Coming 3-10 Years

Sep 18 2025Benzinga

Editas Medicine GAAP EPS of -$0.63 misses by $0.25, revenue of $3.58M beats by $1.78M

Aug 12 2025SeekingAlpha

Gene editors steady despite latest leadership shake-up at FDA

Jun 20 2025SeekingAlpha

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Jun 18 2025Benzinga

This one-and-done heart-disease treatment gets a big endorsement from Eli Lilly

Jun 17 2025MarketWatch

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Jun 12 2025Newsfilter

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method

Jun 12 2025NASDAQ.COM

Insider Sale: SVP of $EDIT Sells 446 Shares

Jun 04 2025NASDAQ.COM